What THERYQ does

THERYQ is a French medical technology company that designs and produces FLASH radiotherapy machines, with a product portfolio built around Very High Energy Electron (VHEE) linear accelerator technology operating at ultra-high dose rates (>100 Gy/s) that deliver radiation in under 100 milliseconds. The underlying FLASH effect spares healthy tissue while maintaining tumor control, and the company's flagship device, FLASHDEEP, targets deep-seated tumors up to approximately 20 cm using 100–200 MeV electron beams. The company was established in 2022 as a spin-off of AVELION — which led pioneering FLASH Radiotherapy research since 2013 — and operates within ALCEN For Health, the healthcare branch of the diversified ALCEN industrial group. THERYQ is headquartered in Paris (6 Rue Paul Baudry, 75008) and runs its office and factory in Rousset, southern France (60 Avenue Olivier Perroy, 13790). Leadership is anchored by founder and CEO Ludovic Meunier, with Fatine Slaoui serving as publication manager. The company is structured as a French simplified joint-stock company (SAS) with €22,843,026 in registered capital and is registered under SIREN 894 194 406.

The core product set comprises FLASHDEEP (a next-generation VHEE FLASH device targeting deep tissue, intended for clinical use once CE marking is granted), FLASHKNiFE (a research-grade FLASH electron platform for superficial lesion research, not commercially available), and FLASHLAB (a collaborative research service built on the Oriatron eRT6 investigational linac, which supported the first-ever patient treatment with FLASH radiotherapy). Supporting infrastructure includes the EN ISO 13485 quality system for medical-device manufacturing (certified by Bureau Veritas) and a Europe-targeted commercialization path being executed jointly with Gustave Roussy under a €38M France 2030 i-Démo grant from Bpifrance.

The business model is currently pre-commercial. Planned revenue streams are anchored on capital hardware sales of FLASHDEEP systems to hospitals and cancer centers once CE-marked, supplemented by FLASHLAB research service agreements and FLASHKNiFE research instruments. Go-to-market is enterprise B2B direct sales into hospitals, cancer treatment centers, and academic research institutions, supported by active participation in ESTRO, ASTRO, SFRO, FRPT, SFPM, and RadioTransNet conferences and by named clinical collaborations with Gustave Roussy, Centre Léon Bérard, Centre Oscar Lambret, and CHUV. Distribution is described as direct enterprise sales with regional (France/Europe) scope and planned global expansion, with custom-quoted pricing and long, consultative sales cycles typical of capital radiotherapy equipment.

Name

THERYQ

Legal name

THERYQ

Website

https://theryq-alcen.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

THERYQ is a French medical technology company that designs and produces FLASH radiotherapy machines using Very High Energy Electron (VHEE) linear accelerators to treat cancer. A 2022 spin-off within the ALCEN group, it serves hospitals, cancer centers, and research institutions with FLASHDEEP, FLASHKNiFE, and FLASHLAB.

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Irradiation Apparatus Manufacturing (334517), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• FLASH radiotherapy devices
• VHEE linear accelerators
• Radiation oncology equipment
• Medical device manufacturing
• Cancer treatment systems

Headquarters

HQ city

Rousset

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (FLASHDEEP): THERYQ generates revenue through the sale of FLASH radiotherapy medical devices (FLASHDEEP systems) to hospitals and cancer treatment centers. The company is building industrial platform for mass production following CE marking approval. Currently pre-commercial with FLASHDEEP not yet clinically available.
2. FLASHLAB Research Systems: Sale of FLASH radiotherapy research systems (FLASHLAB, Oriatron eRT6) to research institutions for pre-clinical and translational research purposes.
3. Professional Services & Consulting: R&D expertise, project management, and technical consulting services related to FLASH radiotherapy development and clinical translation, particularly in partnership with leading cancer research institutions.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

THERYQ designs, develops and manufactures FLASH radiotherapy medical devices using Very High Energy Electron (VHEE) linear accelerator technology that delivers radiation at ultra-high dose rates (>100 Gy/s) in under 100 milliseconds to trigger the FLASH biological effect. Its flagship product FLASHDEEP™ targets deep-seated tumors up to approximately 20 cm with 100-200 MeV electron beams, complemented by the FLASHKNiFE™ research platform for superficial lesions and the FLASHLAB collaborative research service (Oriatron eRT6 investigational linac) for preclinical and translational studies.

Product overview

THERYQ's product portfolio centers on FLASH radiotherapy technology, an innovative radiation technique delivering treatment in a fraction of a second at ultra-high dose rates. The core commercial product is FLASHDEEP™, a next-generation device using Very High Energy Electron (VHEE) beams of 100 to 200 MeV for deep-tissue treatment up to approximately 20 cm. Supporting the research pipeline are FLASHKNiFE™ (a research device for superficial lesions) and FLASHLAB (the Oriatron eRT6 investigational linac service supporting collaborative preclinical studies). The portfolio also encompasses the underlying FLASH radiotherapy technology delivering radiation at ultra-high dose rates exceeding 100 Gy/s, designed to reduce toxicity to healthy tissue while maintaining tumor control.

Differentiator

Problem solved

Functional benefit

Brands

• FLASHDEEP™: A next generation FLASH radiotherapy device using Very High Energy Electron (VHEE) beams of 100 to 200 MeV to treat cancers that resist conventional treatments, designed to target deeper tissues up to approximately 20cm depth.
• FLASHLAB
• FLASHKNiFE™

Products and services

• FLASHDEEP™ Next-generation FLASH radiotherapy medical device using Very High Energy Electron (VHEE) beams of 100-200 MeV delivered via a compact linear accelerator at ultra-high dose rates, enabling treatment of deep-seated and treatment-resistant solid tumors up to approximately 20 cm depth in less than 100 milliseconds. Targeted at hospitals, cancer centers and radiotherapy departments for clinical delivery of FLASH radiotherapy with reduced healthy-tissue toxicity and potential single-session treatment.
• FLASHKNiFE™ Research-grade FLASH radiotherapy system designed for the irradiation of superficial lesions, used for early FLASH research, dosimetric and physicochemical measurements at ultra-high dose rates, radiobiological characterization studies and initial UHDR beam commissioning. Targeted at research institutions and not commercially available.
• FLASHLAB (Oriatron eRT6 Research Service) Collaborative research service offering using the Oriatron eRT6 investigational linear accelerator for preclinical FLASH radiotherapy research projects. Supports dosimetry, radiobiology and translational research in partnership with leading cancer research centers worldwide, including the platform used for the first-ever patient treatment with FLASH radiotherapy.

Quantifiable outcome

• Treatment delivered in less than 100 milliseconds vs. several minutes for conventional radiotherapy
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• AVELIONcoreOthers · 1 January 2022THERYQ is a spin-off of AVELION, which led pioneering FLASH Radiotherapy projects since 2013 with long-standing collaboration with prominent international institutions. In 2022, AVELION transferred the complete radiotherapy activity branch to THERYQ.
• Gustave RoussycoreStrategic or Co-development PartnerTHERYQ and Gustave Roussy (leading French and European cancer research center, ranked 4th worldwide) were selected for the France 2030 i-Démo call for projects for the FLASHDEEP project. The partnership brings together biologists, physicists, and physicians to conduct preclinical and clinical studies to demonstrate improved tolerance and efficacy of FLASHDEEP compared to conventional radiotherapy. Jointly submitting CE marking application for European commercialization.
• Leo Cancer CarecoreStrategic or Co-development PartnerPartnership combining THERYQ's VHEE-FLASH radiotherapy delivery with Leo Cancer Care's upright patient positioning system. Foundation of the FLASHDEEP project, creating more patient-focused cancer care through human-centric treatment approach. Enables face-to-face interaction between patients and therapists during treatment setup.
• ALCEN (ALCEN For Health)coreOthersTHERYQ is part of ALCEN For Health, the healthcare branch of the ALCEN group. Parent company provides corporate resources and group expertise in radiotherapy and medical device manufacturing.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Xstrahl: UK-based manufacturer of research and clinical radiotherapy systems including superficial/orthovoltage units. Comparable as a research-radiotherapy equipment specialist serving similar cancer research institution customers.
• Panacea Medical Technologies: India-headquartered radiotherapy equipment manufacturer offering linear accelerators and brachytherapy systems. Comparable as a regional challenger in the radiotherapy hardware space addressing emerging-market cancer treatment demand.
• IntraOp Medical: Developer of the Mobetron intraoperative electron radiotherapy system. Comparable as a smaller-scale electron-beam radiotherapy specialist targeting niche clinical indications, similar in scope to THERYQ's pre-commercial positioning.

Direct peers

• ViewRay: Developer of MR-guided radiation therapy systems (MRIdian), competing in next-generation adaptive radiotherapy delivery where THERYQ positions FLASHDEEP.
• IBA (Ion Beam Applications): Belgian proton therapy and radiopharmacy solutions provider. Comparable as a European-headquartered particle/radiation therapy hardware company addressing deep-seated tumors with advanced delivery technology.
• Mevion Medical Systems: Compact proton therapy system manufacturer pursuing a cost-effective alternative to conventional proton facilities — a positioning philosophy directly analogous to THERYQ's compact VHEE-FLASH value proposition.
• Elekta: Major radiation therapy equipment manufacturer (Versa HD, Elekta Unity MR-Linac) competing head-to-head in the linear accelerator and radiotherapy delivery category where THERYQ operates.
• RefleXion Medical: Biology-guided radiotherapy company (X1) with a novel delivery modality approach to cancer treatment — comparable as a venture-backed radiotherapy hardware innovator competing for hospital capital budgets.
• Accuray: Developer of CyberKnife and TomoTherapy radiation delivery systems, competing in advanced radiotherapy modalities and sharing THERYQ's enterprise B2B sales motion to hospitals and cancer centers.

Broad incumbents

• Varian (Siemens Healthineers): Global leader in radiation oncology hardware (TrueBeam, Halcyon) and now part of Siemens Healthineers. Directly comparable as the dominant incumbent whose installed base and clinical relationships THERYQ must displace with FLASHDEEP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/theryq

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about THERYQ